Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Bockisch

Showing results (61-70 of 181) with videos related to

Pageof 19
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|July 14, 2010
The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imagingWalter Jentzen, Dorothee Balschuweit, Jochen Schmitz, et al.
Surgery|December 26, 2006
Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumorsAndrea Frilling, Frank Weber, Fuat Saner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 18, 2009
SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancerMonia E Hamami, Thorsten D Poeppel, Stephan Müller, et al.
European Journal of Radiology|December 1, 2009
"One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?Till Heusner, Philipp Gölitz, Monia Hamami, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2002
Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scansGerald Antoch, Lutz S Freudenberg, Thomas Egelhof, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 12, 2007
Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systemsWalter Jentzen, Reiner Weise, Jürgen Kupferschläger, et al.
European Radiology|November 16, 2007
Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancerLutz S Freudenberg, Andrea Frilling, Hilmar Kühl, et al.
Nuclear Medicine Communications|June 6, 2008
Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomographyHilmar Kuehl, Sandra Rosenbaum-Krumme, Patrick Veit-Haibach, et al.
Nuklearmedizin. Nuclear Medicine|March 14, 2018
[Selective intraarterial radiotherapy (SIRT) of malignant liver tumors]Stefan P Müller, Samer Ezziddin, Gerald Antoch, et al.
AJR. American Journal of Roentgenology|November 20, 2002
Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materialsGerald Antoch, Lutz S Freudenberg, Joerg Stattaus, et al.
Pageof 19

Showing results (61-70 of 181) with videos related to

Sort By:
Pageof 19
European Journal of Nuclear Medicine and Molecular Imaging|July 14, 2010
The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imagingWalter Jentzen, Dorothee Balschuweit, Jochen Schmitz, et al.
Surgery|December 26, 2006
Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumorsAndrea Frilling, Frank Weber, Fuat Saner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 18, 2009
SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancerMonia E Hamami, Thorsten D Poeppel, Stephan Müller, et al.
European Journal of Radiology|December 1, 2009
"One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?Till Heusner, Philipp Gölitz, Monia Hamami, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2002
Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scansGerald Antoch, Lutz S Freudenberg, Thomas Egelhof, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 12, 2007
Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systemsWalter Jentzen, Reiner Weise, Jürgen Kupferschläger, et al.
European Radiology|November 16, 2007
Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancerLutz S Freudenberg, Andrea Frilling, Hilmar Kühl, et al.
Nuclear Medicine Communications|June 6, 2008
Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomographyHilmar Kuehl, Sandra Rosenbaum-Krumme, Patrick Veit-Haibach, et al.
Nuklearmedizin. Nuclear Medicine|March 14, 2018
[Selective intraarterial radiotherapy (SIRT) of malignant liver tumors]Stefan P Müller, Samer Ezziddin, Gerald Antoch, et al.
AJR. American Journal of Roentgenology|November 20, 2002
Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materialsGerald Antoch, Lutz S Freudenberg, Joerg Stattaus, et al.
Pageof 19